Inhibition of tumor inflammation and tumor angiogenesis by PPARα ligands might be responsible for theirpotential chemopreventive effects in a variety of experimental models of cancer.However, it must be taken into account that many of the reported effects of PPARα ligands on tumor progression have beenobtained in vitro and await confirmation by additional basic and clinical researchto ascertain whether they can be considered of pharmacological significance invivo. This evidence concerns the gene PPARA and cancer.